Dicembrini, Ilaria
Barbato, Luigi
Serni, Lapo
Caliri, Mariasmeralda
Pala, Laura
Cairo, Francesco
Mannucci, Edoardo http://orcid.org/0000-0001-9759-9408
Funding for this research was provided by:
Università degli Studi di Firenze
Article History
Received: 1 December 2020
Accepted: 12 April 2021
First Online: 17 May 2021
Declarations
:
: Ilaria Dicembrini has received speaking fees from Merck, Novartis, Astra Zeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli-Lilly, Novonordisk, Sanofi, and Novartis. Luigi Barbato, Lapo Serni, Mariasmeralda Caliri, and Laura Pala have no conflicts of interest to declare. Francesco Cairo has received speaking fees from Straumann and Geistlich Biomaterials. Edoardo Mannucci has received consultancy fees from Merck and Novartis speaking fees from Astra Zeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli-Lilly, Merck, Novonordisk, Sanofi, and Novartis and research grants from Merck, Novartis, and Takeda.
: The cross-sectional study was reported in guidance by STROBE guideline. The trial was approved by the Florence Ethical Board (approval number CEAVC 15,563/OSS). All analyses were performed using SPSS 16.0.
: Informed consent was obtained from all study participants.